20
|
Covetrus
ph:
855.724.3461
|
fx:
888.329.3861
|
covetrus.com
MYTH
1
Brand-name drugs go through more
rigorous testing for approval than
private brand generic drugs.
According to the Abbreviated New Animal Drug Application
(ANADA) process, a private brand manufacturer must
show that its generic drug is equivalent to the approved
brand-name drug in three areas:
• Active ingredient
• Strength
• Dosage regimen
Each ingredient must also meet stringent quality standards
and the private brand generic drug must demonstrate
stability over the shelf life of the product.
Blood-level bioequivalence studies are required by the Food
and Drug Administration Center for Veterinary Medicine
(FDA-CVM) for ANADA approval; these studies establish
that any minor difference in bioavailability between
the private brand generic and the brand-name drug is
considered clinically insignificant.
Covetrus Brand Products
Dispelling
common myths
of private
brand drug
alternatives
As consumer perceptions around private brand
generic drugs change, it's important for veterinary
hospitals to offer a variety of options to meet client
demands. Although private brand generic drugs
are commonplace in veterinary healthcare, there
are still some misconceptions about these low-cost
alternatives. For some hospitals, the question on
whether to carry private brand drug options simply
comes down to safety and efficacy: Do private
brand drug alternatives provide equal profiles
compared to "pioneer" (brand-name) drugs?
The answer is an emphatic "yes"! Let's dispel a few
common myths around private brand generic drugs
and discover how offering these alternatives may
help you and your clients save money on treatment
— without sacrificing safety or efficacy.
